Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01607619 · ClinicalTrials.gov registry record · NA
Effect of Anatabine on Elevated Blood Levels of C-reactive Protein
A NA study of Inflammation, sponsored by Roskamp Institute.
- Completed
- Registry status
- NA
- Development phase
- 117
- Enrollment target
- 3
- Study locations
NCT01607619: Completed NA study of Inflammation, sponsored by Roskamp Institute.
NCT01607619 is a NA study of Inflammation that has completed, run by Roskamp Institute. The registered enrollment target is 117 participants, below the 287-participant average among 132 other Inflammation trials with a reported enrollment target (59% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01607619, a NA study of Inflammation, has completed, sponsored by Roskamp Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 117 participants
- Enrollment target
- 3
- Study locations
Study Summary
The investigators are studying a dietary supplement called anatabine in a lozenge form named RCP006. The main purpose of this study is to evaluate the effects of this dietary supplement on normal human inflammatory function. The investigators will see this effect in volunteers who have markers of higher levels of inflammation to begin with. The investigators anticipate that anatabine will reduce markers of inflammation. Therefore the investigators are looking for volunteers with high blood levels of C-reactive Protein (CRP) and will monitor the blood CRP levels at several time points throughout the study.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Anatabine
Study Locations (3)
Michigan
- McLaren Community Medical Center - Flint
- Medical Practice - Shelby
Florida
- The Roskamp Institute, Inc. - Sarasota
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2011-05 |
| Est. Completion | 2013-01 |
| Phase | NA |
What the finished NCT01607619 record still lists
NCT01607619 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, below the 287-participant average among 132 other Inflammation trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Inflammation appearing as the primary indexed condition, and to 1 intervention - of which Anatabine is the first listed.
NCT01607619 reports a single indexed study location in Michigan, Florida.
Frequently Asked Questions
What is clinical trial NCT01607619 about?
NCT01607619 is a clinical study titled "Effect of Anatabine on Elevated Blood Levels of C-reactive Protein". The investigators are studying a dietary supplement called anatabine in a lozenge form named RCP006. The main purpose of this study is to evaluate the effects of this dietary supplement on normal human inflammatory function. The investigators will see this effect in volunteers who have markers of hi...
What is the current status of trial NCT01607619?
This trial is currently completed. It is a NA study. The enrollment target is 117 participants. The study started on 2011-05. Estimated completion is 2013-01.
What conditions does trial NCT01607619 study?
This clinical trial studies the following conditions: Inflammation.
What interventions are being tested in trial NCT01607619?
The interventions under investigation include: Anatabine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01607619?
This trial is sponsored by Roskamp Institute, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01607619 being conducted?
This trial has 3 study locations across Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01607619's enrollment target sits among peer trials
117 41st of 132 higher than 91 of 132 other Inflammation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD
RECRUITING · NA
-
The Iowa ACEs and Sleep Cohort and Manipulating Sleep in Young Adults With ACEs Studies
RECRUITING · NA
-
Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular Zinc
RECRUITING · NA
-
Evaluating Whether Hyperbaric Oxygen Therapy Can Improve VO₂-Max and Reduce Inflammation Markers in Healthy Adults Ages 30-60.
RECRUITING · NA
-
Impact of NMES and HPRO on Recovery After SAH- Pilot Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia